We got a number of important drugs from the Celgene acquisition, says Bristol Myers Squibb CEO

7,894

46 0

Published 2024-01-08

Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk recent acquisitions made by the company, whats ahead for BMY and much more.

All Comments (4)

@jeffreymancini409 14 days ago

The market is disgusted by BMY's 2024 performance
@Alduinsshadow148 5 months ago

With nearly 100 Billion in assets to acquire new drugs and raise prices by 10% each year BMY is one of the cheapest companies in the sp500 to buy as a dividend grower long term also with the aging boomer population healthcare will revert back to the mean.
@jeffreymancini409 9 days ago

OK lets review Dr Boerner's statements from this sixth month old interview: Great Science...the market has done nothing but sell down the value of the company now struggling to maintain $40 a share. Exciting young portfolio: The Celgene purchase, the Karuna purchase, the RayzeBio purchase has done nothing to improve BMY. Exceptional people? Really....the sellers of this stock down to its present distressed level respectfully disagree. Everyone is tired of the snake oil. It's time to get this company back on track.